<DOC>
	<DOCNO>NCT00157157</DOCNO>
	<brief_summary>The purpose study evaluate whether Antihemophilic factor , recombinant , manufacture protein-free ( rAHF-PFM ) effective safe treatment hemophilia A patient treat factor VIII ( FVIII ) .</brief_summary>
	<brief_title>Efficacy Safety Study Recombinant Protein-Free Manufactured Factor VIII ( rAHF-PFM ) Previously Untreated Hemophilia A Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>The subject severe moderately severe hemophilia A defined baseline factor VIII level &lt; = 2 % normal , document screen The subject &lt; 6 year age The subject 's legally authorize representative provide write informed consent The subject history exposure factor VIII rAHF PFM 3 infusion commercially available rAHF PFM ( i.e. , ADVATE ) within 28 day prior screen , determine subject 's medical history . Any infusion factor VIII replacement product prior 28day period excludes subject participation The subject receive 3 infusion rAHF PFM ( commercially available and/or study product ) screen prior initial recovery infusion The subject detectable inhibitor factor VIII , measure screen sample Nijmegen assay central laboratory The subject history inhibitor factor VIII time prior screen The subject know hypersensitivity rAHF PFM The subject 1 follow laboratory abnormality time screening : 1 . Platelet count &lt; 100,000/mm^3 2 . Hemoglobin concentration &lt; 10 g/dL ( 100 g/L ) 3 . Serum creatinine &gt; 1.5 time upper limit normal ( ULN ) age 4 . Total bilirubin &gt; 2 time ULN age The subject inherit acquire hemostatic defect hemophilia A ( e.g. , qualitative platelet defect von Willebrand 's disease ) The subject know seropositive human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis B virus ( HBV ) , determine subject 's medical history At time enrollment , subject clinically significant chronic disease hemophilia A The subject currently participate another investigational drug study , participate clinical study involve investigational drug within 120 day screen visit The subject ( subject 's legally authorize representative ) identify investigator unable unwilling cooperate study procedures The subject receive blood product , include pack red blood cell ( RBC ) , platelet , plasma , cryoprecipitate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Factor VIII Deficiency</keyword>
</DOC>